Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Treatment </td><td align="left">Mechanisms </td><td align="center">References</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Anti-VEGF antibody (bevacizumab)</td><td align="left">Bv8 production in MDSCs</td><td align="center">[<a href="/journals/mi/2015/159269/#B118">118</a>]</td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left">
                Anthracycline/cyclophosphamide</td><td align="left">S100A8/9 production in accumulated MDSCs via secretion of CXCL1/2 by cancer cells </td><td align="center">[<a href="/journals/mi/2015/159269/#B8">8</a>]</td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left">Tyrosine kinase inhibitor (sunitinib)</td><td align="left">Bv8 production in MDSCs<br/>pSTAT5-dependent pathway via GM-CSF production</td><td align="center">[<a href="/journals/mi/2015/159269/#B118">118</a>, <a href="/journals/mi/2015/159269/#B119">119</a>]</td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left">Radiotherapy</td><td align="left">G-CSF-mediated MDSC accumulation</td><td align="center">[<a href="/journals/mi/2015/159269/#B120">120</a>]</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

MDSCs-mediated refractoriness to chemotherapy or radiotherapy.

Mediators of Inflammation

tab1

Table 1

Table 1: Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer 